Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03501979 |
| Title | Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | University of Alabama at Birmingham |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | United States | Details | |
| UCSF-Mission Bay | San Francisco | California | 94158 | United States | Details | |
| MedStar Georgetown University-Lombardi CCC | Washington | District of Columbia | 20007 | United States | Details | |
| University of Chicago | Chicago | Illinois | 60637-1470 | United States | Details | |
| Indiana University-Melvin and Bren Simon cancer center | Indianapolis | Indiana | 46202 | United States | Details | |
| Dana Farber/Harvard Cancer Center- | Boston | Massachusetts | 02215 | United States | Details | |
| University of Michigan- | Ann Arbor | Michigan | 48109 | United States | Details | |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | United States | Details | |
| University of Washington Medical Center-Montlake | Seattle | Washington | 98109 | United States | Details |